» Articles » PMID: 30138305

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2017

Overview
Date 2018 Aug 24
PMID 30138305
Citations 176
Authors
Affiliations
Soon will be listed here.
Abstract

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11-12 years with human papillomavirus (HPV) vaccine, quadrivalent meningococcal conjugate vaccine (MenACWY), and tetanus and reduced diphtheria toxoids and acellular pertussis vaccine (Tdap). A booster dose of MenACWY is recommended at age 16 years (1), and catch-up vaccination is recommended for hepatitis B vaccine (HepB), measles, mumps, and rubella vaccine (MMR), and varicella vaccine (VAR) for adolescents whose childhood vaccinations are not up to date (UTD) (1). ACIP also recommends that clinicians may administer a serogroup B meningococcal vaccine (MenB) series to adolescents and young adults aged 16-23 years, with a preferred age of 16-18 years (2). To estimate U.S. adolescent vaccination coverage, CDC analyzed data from the 2017 National Immunization Survey-Teen (NIS-Teen) for 20,949 adolescents aged 13-17 years.* During 2016-2017, coverage increased for ≥1 dose of HPV vaccine (from 60.4% to 65.5%), ≥1 dose of MenACWY (82.2% to 85.1%), and ≥2 doses of MenACWY (39.1% to 44.3%). Coverage with Tdap remained stable at 88.7%. In 2017, 48.6% of adolescents were UTD with the HPV vaccine series (HPV UTD) compared with 43.4% in 2016. On-time vaccination (receipt of ≥2 or ≥3 doses of HPV vaccine by age 13 years) also increased. As in 2016, ≥1-dose HPV vaccination coverage was lower among adolescents living in nonmetropolitan statistical areas (MSAs) (59.3%) than among those living in MSA principal cities (70.1%). Although HPV vaccination initiation remains lower than coverage with MenACWY and Tdap, HPV vaccination coverage has increased an average of 5.1 percentage points annually since 2013, indicating that continued efforts to target unvaccinated teens and eliminate missed vaccination opportunities might lead to HPV vaccination coverage levels comparable to those of other routinely recommended adolescent vaccines.

Citing Articles

Human papillomavirus vaccination coverage among adolescent boys and girls in the United States: A birth year cohort analysis of the National Immunization Survey-Teen, 2016-2022.

Nyika P, Yankey D, Elam-Evans L, Meyer S, Pingali C, Stokley S Vaccine. 2024; 44():126560.

PMID: 39615345 PMC: 11694783. DOI: 10.1016/j.vaccine.2024.126560.


Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults.

Shin T, Wells C, Shoukat A, Potter-Schwartz L, Langevin E, Langley J JAMA Netw Open. 2024; 7(11):e2443551.

PMID: 39504021 PMC: 11541638. DOI: 10.1001/jamanetworkopen.2024.43551.


Association Between a Mother's Cervical Cancer Screening and Child's Human Papillomavirus (HPV) Vaccination Status.

Bloom A, Springer R, Angier H, Heintzman J, Likumahuwa-Ackman S, Huguet N Matern Child Health J. 2024; 28(12):2137-2146.

PMID: 39379736 PMC: 11790011. DOI: 10.1007/s10995-024-03998-0.


Prevalence and genotype distribution of HPV combined with cervical pathological results in women from Sichuan, China: A cross-sectional study based on post-vaccination period 2019 to 2023.

Mo B, Ye Y, Yu M, Tong X, Cao H, Du C Cancer Med. 2024; 13(16):e70148.

PMID: 39189602 PMC: 11348228. DOI: 10.1002/cam4.70148.


An In Vitro Investigation of the Antiproliferative and Antimetastatic Effects of Levosimendan: Potential Drug Repurposing for Cervical Cancer.

Schelz Z, Muddather H, Jaski F, Bozsity N, Zupko I Curr Issues Mol Biol. 2024; 46(7):6566-6579.

PMID: 39057033 PMC: 11275392. DOI: 10.3390/cimb46070391.


References
1.
Markowitz L, Gee J, Chesson H, Stokley S . Ten Years of Human Papillomavirus Vaccination in the United States. Acad Pediatr. 2018; 18(2S):S3-S10. PMC: 11331487. DOI: 10.1016/j.acap.2017.09.014. View

2.
Shipman S, Lan J, Chang C, Goodman D . Geographic maldistribution of primary care for children. Pediatrics. 2010; 127(1):19-27. PMC: 3010089. DOI: 10.1542/peds.2010-0150. View

3.
Mohammed K, Subramaniam D, Geneus C, Henderson E, Dean C, Subramaniam D . Rural-urban differences in human papillomavirus knowledge and awareness among US adults. Prev Med. 2018; 109:39-43. DOI: 10.1016/j.ypmed.2018.01.016. View

4.
MacNeil J, Rubin L, Folaranmi T, Ortega-Sanchez I, Patel M, Martin S . Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(41):1171-6. DOI: 10.15585/mmwr.mm6441a3. View

5.
Walker T, Elam-Evans L, Singleton J, Yankey D, Markowitz L, Fredua B . National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2016. MMWR Morb Mortal Wkly Rep. 2017; 66(33):874-882. PMC: 5687818. DOI: 10.15585/mmwr.mm6633a2. View